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Abstract
Objective: To investigate effects of lipid lowering drug, simvastatin, on apolipoprotein M expression in the
hyperlipidemic mice and in hepatic cell line, HepG2 cells.
Methods: Swiss male mice were randomly divided into the high fat group and control group, and were
intragastrically fed with 0.9% saline (control group) or lipid emulsion (high fat group) at the daily dosage of 15 ml/
kg body weight, respectively. After 8 weeks feeding, the hyperlipidemic model was successfully induced and these
hyperlipidemic mice were then randomly divided into three experimental groups: vehicle control group, high-dose
simvastatin-treated group (100 mg/kg body weight), and low-dose simvastatin-treated group (10 mg/kg body
weight). Mice were dosed daily for 6 weeks of simvastatin before mice were sacrificed for determining serum lipid
profile and apoM protein levels that was determined by using dot blotting analysis. Effects of simvastatin on apoM
mRNA expression in the HepG2 cells were determined by real-time RT-PCR.
Results: Comparing to high fat model mice without simvastatin treatment, 100 mg/kg simvastatin could
significantly increase serum total cholesterol (P < 0.05). Serum apoM levels, in all mice, were significantly lower in
the mice at the age of 26 weeks than the mice at 12 weeks old (P < 0.05), which indicated that serum apoM levels
were significantly correlated to the mice age. It demonstrated also that treatment of simvastatin did not influence
serum apoM levels in these mouse model, although serum apoM levels were increased by about 13% in the 10
mg/kg simvastatin group than in the vehicle control group without simvastatin. In HepG2 cell cultures, simvastatin
could significantly decrease apoM mRNA levels with dose- and time-dependent manners. At 10 μM simvastatin
treatment, apoM mRNA decreased by 52% compared to the controls.
Conclusion: The present study suggested that simvastatin, in vivo, had no effect on apoM levels in the
hyperlipidemic mouse model. ApoM serum levels in mice were significantly correlated to the animal’s age, whereas
in cell cultures simvastatin does inhibit apoM expression in the HepG2 cells. The mechanism behind it is not
known yet.
Introduction
Apolipoprotein M(apoM) is one of the latest discovered
lipoprotein-associated plasma protein that is mainly
synthesized in the liver, and to a smaller amounts, in
the kidney [1]. In human plasma, most apoM are found
in high-density lipoproteins (HDL) and small proportion
present also in the apoB-containing lipoproteins, i.e.
chylomicrons, very low-, and low-density lipoproteins
(VLDL and LDL) [1,2]. Recent investigation has
demonstrated that apoM may participate in the HDL-
related biological activities as an important component
of HDL particle on the protection of endothelial cells
[3]. Wolfrum, et al., [4] reported that apoM is required
for preb-HDL formation and cholesterol efflux to HDL
as described for an initial and crucial stage of reverse
cholesterol transport, and subsequently protects against
atherosclerosis. In addition, the physiological and patho-
physiological roles of apoM may also involve in the
inflammatory activities and the potential immuno-and
inflamm-reactive property of apoM may contribute to
the anti-inflammatory function of HDL [5,6]. The statin
class of drugs inhibits the enzyme 3-hydroxy-3-
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which is the first committed step of sterol synthesis,
lead to a lowering of plasma cholesterol levels. In several
large clinical trials, the use of statins reduces coronary
events. Simvastatin has been shown to reduce total mor-
tality rates in patients with coronary heart disease [7].
Previous studies have shown that the plasma apoM con-
centration is positively correlated with leptin levels and
negatively correlated with total cholesterol in normal and
obese subjects [8]. ApoM gene expression could be
directly regulated by transcription factors including
transforming growth factor (TGF)-b, hepatic nuclear fac-
tor (HNF)-1a, liver receptor homolog (LRH)-1 and fork-
head box A2 (Foxa2), all these could regulate hepatic
lipid metabolism [9-12]. This may indicate that apoM is
involved in lipid and glucose homeostasis. Evidence from
different individual laboratories suggests that HMG-CoA
reductase inhibitors can down-regulated apoA-IV apoB,
apoC-III and apoE, while apoA-I was up-regulated in ani-
mal models and cultured hepatocytes [13]. The effect of
simvastatin on apoM has not been studied. To examine
whether cholesterol-lowering with statin therapy impact
on plasma apoM concentration may provide greater
insight into the role of apoM in human lipoprotein meta-
bolism. In this study, we investigated if apoM expression
is regulated by simvastatin in vivo and in vitro.
Materials and methods
Cells, animals, and reagents
The human hepatoblastoma cell line, HepG2, was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA). Male Swiss mice were pur-
chased from Shanghai Slac Laboratory Animal Co.
(Shanghai, China). Simvastatin was purchased from
International Laboratory Co.(Utah, OREM, USA). Cho-
lesterol, Propylthiouracil and Tween-80 were from
Sigma Aldrich (St Louis, USA). Deoxycholic acid sodium
salt was obtained from Merck (Germany). ABI PRISM
7700 sequence detection system, real-time RT-PCR
reagents and control probe GAPDH were purchased
from the Applied Biosystems Inc. (Foster City, CA,
USA). Rabbit anti-mouse apoM was from Abnova Cor-
poration, Taiwan. Alkaline phosphatase (AP) conjugated
Affinipure goat anti-rabbit IgG was from Jackson Immu-
noresearch Laboratories, Inc., USA. BCIP/NBT Color
Development Substrate was from Sino-American Bio-
technology Company (Luoyang, China). Quantity One
Software V4.6.2 was from Bio-Rad. Cell culture flasks
(25 cm
2) and 6-well cell culture clusters were from
Costar, USA.
Animal experiments
Fifty male Swiss mice weighing 30-32 g, at 12-weeks old,
were subjected in the study. Mice were acclimatized one
week prior to the experiment and were housed in stan-
dard cages at 22°C and 40-60% relative humidity with a
12-hrs light/dark cycle, maintained on standard chow
and water ad libitum. The mice were randomly assigned
to and housed in ten different cages containing sawdust
bedding. For inducing hyperlipidemia, mice were fed on
a lipid emulsion that contains 20% (g/100 g) fat of lard,
10% cholesterol, 2% deoxycholic acid sodium salt, 1%
propylthiouracil, 10% Tween-80 and double-distilled
water. Mice were randomly divided into two groups, i.e.,
high fat group (fed lipid emulsion) and control group
(fed 0.9% saline) at the daily dosage of 15 ml/kg body
weight, respectively. After 8 weeks feeding, thirty-nine
hyperlipidemic mice successfully induced, which were
randomly divided into three experimental groups. And
then animals were dosed daily via oral gavage with 10
or 100 mg/kg simvastatin in 0.5% methylcellulose or
administered methylcellulose alone (vehicle control)
starting at 20 weeks of age. After 6 weeks, mice were
anesthetized and sacrificed. Blood samples were taken
through tail vein and the serum was centrifuged and
stored at -80°C. The housing care of the animals and all
the procedures used in these studies were performed in
accordance with the guidelines and regulations of the
University of Suzhou Institutional Animal Care and Use
Committee.
Cell cultures
H e p G 2c e l l sw e r eg r o w ni nR P M I1 6 4 0w i t h1 0 %f e t a l
calf serum (FCS) in the presence of benzylpenicillin (100
U/ml) and streptomycin (100 μg/ml) under standard
culture conditions (5% CO2, 37°C). Cells were seeded in
25-cm
2 cell culture flasks or in 6-well cell culture clus-
ters, and grown to 50-70% confluence.
Prior to experiments, cells were washed twice with
p h o s p h a t eb u f f e r e ds a l i n e( PBS) and once with serum-
free RPMI 1640 without antibiotics. Then the experi-
mental medium, containing RPMI 1640 with 0.5%
human serum albumin (HSA) and different concentra-
tions of simvastatin (0 μM, 3 μM, 5 μM,10 μM, and 30
μM) were added. Cells were incubated at 37°C with dif-
ferent time intervals.
Isolation of total RNA and real-time RT-PCR
Total RNA of HepG2 cells was isolated by the guanidi-
nium thiocyanate method [14]. Primer Express software
(Applied Biosystems) was used to design human apoM
primers and probes based on the TaqMan assay. In
order to avoid amplifying the DNA template, the apoM
specific primers that are spanned an 81-bp intron was
designed to amplify a 66-bp product. The primers were
5’-tgccccggaaatggatcta and 5’-cagggcggccttcagtt, and the
probe was 5’-FAM-cacctgactgaagggagcacagatctca-
TAMRA. Relative standard curves for apoM and
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ciency of PCR. A serial dilution of human apoM cDNA
was used to generate a standard curve by plotting the
cycle threshold versus the log of input cDNA. The
apoM and GAPDH standards were linear with the input
of cDNA. Quantification of apoM mRNA levels is rela-
tive to GAPDH mRNA levels, and was performed on an
ABI PRISM 7700 Sequence Detector. The real-time RT-
PCR was performed in two steps in a 25 μl reaction
mixture containing 1 μl TaqMan Universal PCR Master
Mix, 22.5 pmol of both forward and reverse primers, 5
pmol probes and 50 ng of the total RNA templates.
Thermal cycling conditions included the following steps:
25°C 10 min, 48°C 30 min, and 95°C 5 min to do
reverse transcription, and then the reaction mixture was
preheated for 2 min at 50°C and for 10 min at 95°C to
activate Taq polymerase. After that, a 40-cycle two-step
PCR was performed consisting of 15s at 95°C and 1 min
at 60°C. All experiments were performed at least three
times in triplicate.
Determination of serum apoM
Serum apoM levels were semi-quantitatively examined
by a dot-blot analysis with a specific rabbit anti-mouse
apoM antibody. Two-microliter serum samples were
applied to the Hybond-C membrane in triplicate. All
samples were applied to the same membrane. The mem-
brane was quenched in Tris-HCl buffer in presence of
4% Tween and 3% BSA for 3 hrs, and sequentially incu-
bated with primary antibody (1:1000 dilution in Tris-
HCl buffer) overnight at 4°C. After washing by Tris-HCl
buffer three times membrane was then incubated with
AP conjugated secondary antibody for 2 hrs at room
temperature. The development of AP activity was per-
formed with a commercial visualization system accord-
ing to the manufacturer’s instructions. The relative
amount of apoM were analyzed with Quantity One Soft-
ware, and presented as volume (intensity*mm
2).
Statistical analyses
Statistical analysis was performed with Graphpad Prism
5.0 software (GraphPad Software Inc.). Results are
expressed as means ± SEM. Multiple comparisons were
performed with one-way ANOVA/Turkey, and
comparisons between after and before simvastatin treat-
ment of each group were statistically evaluated by the
paired t-test. Significance was established at a P value
less than 0.05.
Results
Serum lipid profile in mice after a high fat diet and
effects of simvastatin on serum levels of lipid and apoM
As shown in table 1, the serum profile of LDL-choles-
terol, total cholesterol were significantly increased in the
mice under oral gavaged for 8 weeks compared to the
control group by 154% and 85%, respectively. Serum tri-
glycerides were didn’t change after 12 weeks high fat
feeding, whereas after 20 weeks feeding, serum triglycer-
ides were even slightly decreased in these mice com-
pared to controls. In the hyperlipidemic mice after
treated with simvastatin, either in the low dose (10 mg/
kg body weight) or high dose (100 mg/kg body weight),
unexpectedly, serum total cholesterol levels were signifi-
cantly increased compared to the vehicle control mice
and normal control mice (Table 2). The same phenom-
enon was seen in LDL-cholesterol levels too. As shown
in Figure 1, there were no statistical significant differ-
ences on serum apoM levels in these mice at 26 weeks,
although serum apoM levels were slightly increased
(about 13%) in the 10 mg/kg simvastatin-treated mice
compared to the vehicle control mice (Figure 1). As
shown in Figure 2, serum apoM levels, in all mice, were
dramatically lower in the mice at the age of 26 weeks
than in the mice at 12 weeks old (P < 0.05). At the 26
th week, serum apoM levels were decreased by 26% (P <
0.01) and 17% (P < 0.05), respectively, compared to 12
or 20 weeks of normal control mice. It is also demon-
strated that neither low dose (10 mg/kg body weight)
nor high dose (100 mg/kg body weight) influence serum
apoM levels.
Effects of simvastatin on apoM mRNA levels in HepG2 cell
cultures
As shown in Figure 3, simvastatin could significantly
inhibited apoM expression in the HepG2 cells, with
dose- and time-dependent manners. Simvastatin at 10
μM decreased apoM mRNA in HepG2 cells by about
52% compared to the controls (P < 0.01) (Figure 3).
Table 1 Serum lipid profile in mice fed a high fat diet
Lipids
(mmol/L)
Control diet High fat diet
12 weeks 20 weeks P 12 weeks 20 weeks P
TC 2.44 ± 0.22 2.64 ± 0.20 P > 0.05 2.97 ± 0.09 4.89 ± 0.18 P < 0.0001
LDL-C 0.40 ± 0.03 0.40 ± 0.02 P > 0.05 0.47 ± 0.01 0.99 ± 0.05 P < 0.0001
HDL-C
TG
1.53 ± 0.10
1.53 ± 0.10
1.61 ± 0.12
1.67 ± 0.15
P > 0.05
P > 0.05
1.73 ± 0.06
1.57 ± 0.07
1.69 ± 0.06
0.98 ± 0.04
P > 0.05
P < 0.0001
Data are shown as means ± SEM. TC (total cholesterol), HDL-C (high density lipoprotein cholesterol), LDL-C (low density lipoprotein cholesterol), TG (triglyceride).
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ApoM is one of the latest discovered human apolipopro-
tein predominantly present in HDL in human plasma,
and its physiological and patho-physiological roles
remain to be clarified [1]. Experiments in transgenic
mice suggested apoM may have anti-atherogenic proper-
ties and the possible mechanisms include increased for-
mation of pre-b HDL, enhanced cholesterol
mobilization from foam cells, and increased antioxidant
properties [2,4]. Statins, inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, have
revolutionized the treatment of hypercholesterolemia.
They are the most efficient agents for reducing plasma
cholesterol, being also appreciated for their good toler-
ance. Angiographic studies have demonstrated that
these compounds reduce the progression and may
induce the regression of atherosclerotic lesion in cardio-
vascular vessels, which could lead to a significant
decreases of cardiovascular morbidity and mortality [15].
Statins have been shown to inhibit hepatic production
of apoA-IV apoB, apoCIII and apoE-containing lipopro-
teins both in vitro and in vivo [13,16].
In the present study, we demonstrated that simvasta-
tin, in vivo, had no effect on apoM levels in the
hyperlipidemic mouse model or in normal mice. Inter-
estingly apoM serum levels in mice were significantly
correlated to the animal’s age. In wild-type mouse
plasma, cholesterol was predominantly found in HDL
and apoM was also recovered in the same fractions as
HDL [17]. This may partly explain the reason why nor-
mal control mice had a pronounced decrease in HDL
cholesterol [18]. The detailed mechanism needs further
investigation. However, in HepG2 cell cultures, simvas-
tatin does inhibit apoM expression. We don’th a v et h e
reasonable explanation on such difference between the
animal models and cell cultures. In addition, in the pre-
sent study, we demonstrated that serum triglyceride
levels were significantly decreased in the high fat diet
group mice compared to normal control mice at 20
weeks, which may be possible that the high fat diets
contain some cholates. As a bile salt, it is a ligand for
the nuclear hormone receptor FXR, whose activity regu-
lates the expression of multiple genes involved in lipo-
protein metabolism. Among these genes are apoCII and
apoCIII, whose alterations of expression could account
for the fact that the presence of cholate in the diet is
associated with a lower plasma triglyceride than is the
Table 2 Effects of simvastatin on serum lipid levels (mmol/L)
Groups N TC TG HDL-C LDL-C
Normal control 6 2.39 ± 0.17 2.30 ± 0.26 0.27 ± 0.03 0.26 ± 0.02
Vehicle control 9 3.59 ± 0.22
a 1.58 ± 0.11
b 1.17 ± 0.10
b 0.73 ± 0.06
b
Simvastatin (10 mg/kg) 10 3.84 ± 0.18 1.19 ± 0.08 1.34 ± 0.12 0.76 ± 0.04
Simvastatin (100 mg/kg) 14 4.49 ± 0.25* 1.33 ± 0.09 1.59 ± 0.17 0.93 ± 0.09
Data are shown as means ± SEM. TC (total cholesterol), HDL-C (high density lipoprotein cholesterol), LDL-C (low density lipoprotein cholesterol), TG (triglyceride).
*P < 0.05 vs. vehicle control,
aP < 0.05 vs. normal control,
bP < 0.01 vs. normal control.
Figure 1 Serum apoM levels in mice treated with simvastatin
for 6 weeks. ApoM concentrations were determined by dot-
blotting analyses as described in the materials and methods. Data
are expressed as the intensity*mm
2 that was analyzed by the
software of Quantity One. Data are means ± SEM.
Figure 2 Serum apoM levels in mice at different time intervals.
ApoM concentrations were determined by dot-blotting analyses as
described in the materials and methods. Data are expressed as the
intensity*mm
2 that was analyzed by the software of Quantity One.
Data are means ± SEM. *P < 0.05 vs. 20-week normal control, **P <
0.01 vs. 12-week normal control.
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to note that simvastatin could elevate serum cholesterol
in Swiss mice when dosed at 100 mg/kg body weight/
daily for 6 weeks in this study, which is consistent with
previous observations by Wang et al [20], who reported
that simvastatin could increase serum cholesterol in
mice. The mechanism responsible for this unexpected
increase of serum cholesterol is unknown yet. One possi-
ble explanation may be related to the discrepancies of
various species. It may also be possible that higher con-
tinuous dose of simvastatin had stimulatory effects on
the expression and activity of 3-hydroxy-3-methylglutaryl
coenzyme A reductase in the liver [21], which lead to an
increased cholesterol levels in these mice. The detailed
mechanism needs further investigation.
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